We thank past and present members in JCT and LM-S laboratories for the development and improvement of the arenavirus reverse genetics techniques and plasmids. We also thank Snezhana Dimitrova for technical support. The monoclonal antibody directed to JUNV NP (SA02-BG12) was obtained from BEI Resources (NIAID Biodefense and Emerging Infections Research Resources Repository). BYHC was supported by Grant Number GM068411 from Institutional Ruth L. Kirschstein National Research Service Award. EO-R is a Fullbright-Conicyt (BIO 2008) and a Rochester Vaccine Fellowship (2012) recipient. EO-R current support is provided by a postdoctoral Fellowship for Diversity &amp; Academic Excellence from the Office for Faculty Development &amp; Diversity at the University of Rochester. Research in LM-S laboratory is funded by the NIH grants RO1 AI077719, R21NS075611-01, R03AI099681-01A1, the NIAID Centers of Excellence for Influenza Research and Surveillance (HHSN266200700008C), and The University of Rochester Center for Biodefense Immune Modeling (HHSN272201000055C).
Research at JCT laboratory was supported by grants RO1 AI047140, RO1 AI077719, and RO1 AI079665 from NIH.

1. Arenavirus Rescue Transfection
Our rescue system was based on the use of both polymerase II protein expression plasmids encoding the nucleoprotein (NP) and RNA-dependent-RNA-polymerase (L), the viral trans-acting factors required for RNA replication and gene expression of the arenavirus genome 7, 19 , and plasmids capable to direct intracellular synthesis, via the cellular RNA polymerase I (pol-I), of the S and L antigenome RNA species 7 . In our studies we use the pCAGGs protein expression plasmid, which uses the chicken &beta;-actin promoter and polyadenylanation (pA) signal sequences, and the human pol-I plasmid, which uses the human polymerase I promoter and murine terminator sequences (Figure 2). The S and L RNA segments are cloned into the hpol-I plasmid in an antigenomic orientation to allow for the generation of genomic RNA segments upon transcription by hpol-I. For the rescue of wild-type recombinant LCMV (rLCMV) and Candid#1 (rCandid#1) the pCAGGs NP and L from each virus were co-transfected together with their respective human pol-I S and L RNA segments (Figure 3). Generation of recombinant trisegmented LCMV (r3LCMV) and Candid#1 (r3Candid#1) followed a similar protocol but the S segment was split into two different pol-I S plasmids, each encoding a distinctive reporter gene: in one, the NP open reading frame (ORF) was replaced with the Green Fluorescent Protein (GFP) reporter gene (hpol-I S GFP/GP) and, in the other, the viral glycoprotein precursor (GPC) ORF is replaced with the Gaussia luciferase (Gluc) reporter gene (hpol-I S NP/Gluc). A schematic representation of the protocol is illustrated in Figure 4. The following transfection and infection protocol has been established for 6-well-plates.
<ol>
	<li>OptiMEM-Lipofectamine 2000 (LPF2000) mixture: Prepare 250 &mu;l of OptiMEM media and, depending on the virus rescue, 10 - 12 &mu;g of LPF2000 (1 &mu;g/&mu;l) per transfection (Table 1). A ratio of 2.5 &mu;g LPF2000 per &mu;g of DNA is recommended. Incubate for 5 - 10 min at RT. Meanwhile, prepare the plasmid transfection mixture in a separate microcentrifuge tube (step 1.2).</li>
	<li>Plasmid DNA transfection mixture: Prepare the plasmid transfection cocktail in a microcentrifuge tube using the recommended amounts for each virus rescue (see Table 1). Bring the final volume to 50 &mu;l with OptiMEM.</li>
	<li>OptiMEM-LPF2000-DNA plasmid mixture: Add 250 &mu;l of the OptiMEM-LPF2000 mixture (step 1.1) into the plasmid DNA transfection mixture (step 1.2). Incubate this mixture for 20 - 30 min at RT. Meanwhile prepare and count 1 x 106 Vero cells per transfection reaction. Vero cells will be transfected in suspension.</li>
	<li>Preparation of Vero cells: Vero cells are cultured in 100 mm dishes. Before starting, bring the 1x PBS, DMEM 10% FBS 1% PS media, and trypsin-EDTA mixture to 37 &deg;C.
	<ol>
		<li>Wash cells, twice, with 5 ml of 1x PBS.</li>
		<li>Trypsinize cells with 1 ml of trypsin-EDTA and wait until cells detach (approximately 5 min). Gentle tapping maybe required to fully detach the cells from the dishes.</li>
		<li>Carefully, resuspend the cells in 10 ml of DMEM 10% FBS 1% PS in a 15 ml centrifuge tube.</li>
		<li>Centrifuge the cells for 5 min at 1,000 rpm in a centrifuge.</li>
		<li>Resuspend the cells in 10 ml of DMEM 10% FBS 1% PS and count the cells using a hemocytometer and adjust concentration to 1 x 106 cells/ml. It was observed that 0.5 - 1 x 106 Vero cells per transfection produced the best results.</li>
	</ol>
	</li>
	<li>Mix LPF2000/DNA and cells: After 20 - 30 min room temperature incubation (step 1.3), add 1 ml of Vero cells (1 x 106) (step 1.4) to the OptiMEM-LPF2000-DNA plasmid mixture and incubate for 5 min at room temperature.</li>
	<li>Seed LPF2000/DNA-cell mix into 6-well-plates: Add the DNA-LPF2000-Vero mixture (step 1.5) into the wells of the 6-well plate. Gently shake the 6-well-plate and let the transfection incubate overnight in the incubator at 37 &deg;C and 5% CO2.</li>
	<li>Change transfection medium: Approximately 16 - 24 hr post-transfection, remove the transfection media, add 2 ml of infection media and incubate transfected cells for an additional 48 hr.</li>
	<li>Cell passage: After 48 hr of incubation in infection media, remove the tissue culture supernatant (TCS) and pass the transfected cells into a 100 mm dish. The TCS rarely contains infectious virus because the transfected cells need additional incubation to generate virus particles. For the cell passage:
	<ol>
		<li>Wash cells, twice, with 2 ml of 1x PBS.</li>
		<li>Trypsinize cells with 0.5 ml of trypsin-EDTA and wait until cells detach.</li>
		<li>Resuspend the cells in 1 ml of DMEM 10% FBS 1% PS in a 1.5 ml microcentrifuge tube.</li>
		<li>Centrifuge the cells for 5 min at 5,000 rpm, 4 &deg;C in a microcentrifuge.</li>
		<li>Carefully resuspend the cells in 1 ml of infection media and transfer the cells to a 100 mm dish. Bring up the total volume in the plate, with infectious media, to 8 ml, a sufficient volume to prevent drying of the cells as well as for concentrating the virus.</li>
	</ol>
	</li>
	<li>Gently shake the 100 mm dish and continue the incubation of Vero cells in the incubator at 37 &deg;C and 5% CO2 for 72 hr.</li>
	<li>Collection of TCS: After 72 hr incubation, collect the TCS in a 15 ml centrifuge tube. Remove cell debris by centrifuging for 5 min at 2,500 rpm in a centrifuge. Infectious arenavirus is found in the TCS, so remove from the cell debris pellet and store the TCS at -80 &deg;C.</li>
</ol>
2. Confirmation of Recombinant Arenavirus Rescue
Detection of a successful rescue of rLCMV and rCandid#1 is achieved via a focus forming unit (FFU) immunofluorescence assay (IFA). For wild-type virus rescue we use antibodies specific for the viral NP. The r3LCMV and r3Candid#1 encode two reporter genes (GFP and Gluc), thus allowing viral detection and titration without the need of antibodies by fluorescence microscopy (GFP) and/or luminescence (Gluc).
<ol>
	<li>Confirm wild-type recombinant arenavirus rescue: The day before titration, wash Vero cells twice with PBS, trypsinize and prepare 96-well plates to reach 80 - 90% confluence next day (4 x 104 cells/well). Gently shake the plates by hand to get a uniformed distribution of the cells. Culture the cells, overnight, in the 37 &deg;C incubator with 5% CO2. Check the cells under the microscope to confirm a monolayer, before proceeding with the infection:
	<ol>
		<li>Serially dilute (10 fold dilutions) the virus-containing TCS recovered from the transfected cells in the 100 mm dish (step 1.10) in OptiMEM.</li>
		<li>Remove media from the seeded Vero cells, wash twice with 50 &mu;l of 1x PBS, and infect cells with 50 &mu;l of the serially diluted virus (step 2.1). Infect cells for 1.5 hr at 37 &deg;C and 5% CO2.</li>
		<li>After infection, remove the virus inoculum, add 100 &mu;l of infection media/well and incubate the cells for 16 - 18 hr. Viral re-infection may occur after 18 hr incubation, which could result in over-estimation of the viral titers.</li>
		<li>At 16 - 18 hr post-infection, remove the TCS from each well and fix the cells with 4% formaldehyde diluted in 1x PBS, for 15 min at RT.</li>
		<li>Next, remove the fixation solution and permeabilize the cells with 0.1% triton X-100 diluted in 1x PBS, for 10 min at room temperature.</li>
		<li>Aspirate the permeabilization solution, then wash cells 3 times with 1x PBS.</li>
		<li>Block the cells with 2.5% albumin bovine serum (BSA) in 1x PBS (blocking solution) for 1 hr at RT. Alternatively, the cells can be blocked overnight at 4 &deg;C and continued with antibody incubation the following day.</li>
		<li>Meanwhile prepare the primary antibody. Dilute the LCMV- and Candid#1-specific primary antibodies in blocking solution, and then centrifuge the antibody/blocking solution for 15 min at 3,500 rpm. The monoclonal anti-LCMV NP antibody clone 1.1.3 (1:30 dilution) 16 and the monoclonal anti-JUNV NP antibody SA02-BG12 from BEI Resources (1:500 dilution) can be used for the detection of rLCMV and rCandid#1, respectively.</li>
		<li>After a 1 hr incubation, aspirate the blocking solution and add 50 &mu;l of the primary antibody to the cells and incubate for 1 hr at 37 &deg;C.</li>
		<li>At this time, dilute the secondary antibody in blocking solution, and then centrifuge the antibody/blocking solution for 15 min at 3,500 rpm. The polyclonal rabbit anti-mouse IgG FITC secondary antibody for the detection of primary monoclonal antibodies was used to obtain images observed in Figure 5.</li>
		<li>After 1 hr incubation, aspirate the primary antibody, wash 3 times with 1x PBS, and add the secondary antibody for 30 min at 37 &deg;C.</li>
		<li>Following 30 min incubation, aspirate the secondary antibody and wash 3 times with 1x PBS. The cells are now ready to be observed using fluorescence microscopy to both determine the success of viral rescue and titration by counting the focus forming units per ml (FFU/ml).</li>
	</ol>
	</li>
	<li>r3LCMV and r3Candid#1 viral rescue: Since these viruses express two reporter genes, their rescues can be monitored by fluorescence microscopy to detect GFP expression or Gluc expression in TCS. Rescue can be also confirmed by expression of Gluc in TCS. To titrate the trisegmented viruses, we follow steps 2.1 to 2.1.4, however cells do not need to be fixed to determine a successful viral rescue because of GFP expression. The titration of the virus will be determined by counting the FFU/ml. To determine successful viral rescue by Gluc expression, Gluc expression from TCS can be measured using a Gluc assay kit (Biolux Gaussia Luciferase Assay kit, New England Biolabs). To that end:
	<ol>
		<li>Pipet 100 &mu;l of TCS into a 96-well white plate (Flat bottom microtiter plates, Fisher Scientific).</li>
		<li>Set up the luminometer (LumiCount, Packard Biosciences).</li>
		<li>Add 50 - 100 &mu;l Gluc Assay solution (as recommended by the manufacturer) to each sample and measure the Gluc reporter gene expression with the luminometer. As a negative control, Gluc expression of the TCS from the wild-type viruses infected cells was measured.</li>
	</ol>
	</li>
</ol>
3. Passage of Tissue Culture Supernatants
Viral rescue depends on transfection efficiencies. Vero cells have been shown to have lower transfection efficiencies than other cell lines 14 . If virus titers in the TCS are low, infect fresh Vero cells at a multiplicity of infection (MOI) of 0.01 (LCMV) or 0.1 (Candid#1) for 72 hr to amplify the virus.

<ol>
	<li>Albarino, C. G., Bird, B. H., Chakrabarti, A. K., Dodd, K. A., Flint, M., Bergeron, E., White, D. M., Nichol, S. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+major+determinant+of+attenuation+in+mice+of+the+Candid1+vaccine+for+Argentine+hemorrhagic+fever+is+located+in+the+G2+glycoprotein+transmembrane+domain.">The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.</a> Journal of Virology. 85, 10404-10408 (2011).</li><li>Barton, L. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymphocytic+choriomeningitis+virus:+a+neglected+central+nervous+system+pathogen.">Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen.</a> Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America. 22, 197 (1996).</li><li>Buchmeier, M. J., Peter, C. J., de la Torre, J. C., Fields, B. N., Knipe, D. M., Howley, P. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Arenaviridae:+The+viruses+and+their+replication.">Arenaviridae: The viruses and their replication.</a> Fields' Virology. 2, 179201827 (2007).</li><li>Emonet, S. E., Urata, S., de la Torre, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Arenavirus+reverse+genetics:+new+approaches+for+the+investigation+of+arenavirus+biology+and+development+of+antiviral+strategies.">Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies.</a> Virology. 411, 416-425 (2011).</li><li>Emonet, S. F., Garidou, L., McGavern, D. B., de la Torre, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+recombinant+lymphocytic+choriomeningitis+viruses+with+trisegmented+genomes+stably+expressing+two+additional+genes+of+interest.">Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest.</a> Proceedings of the National Academy of Sciences of the United States of America. 106, 3473-3478 (2009).</li><li>Fischer, S. A., Graham, M. B., Kuehnert, M. J., Kotton, C. N., Srinivasan, A., Marty, F. M., Comer, J. A., Guarner, J., Paddock, C. D., DeMeo, D. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Transmission+of+lymphocytic+choriomeningitis+virus+by+organ+transplantation.">Transmission of lymphocytic choriomeningitis virus by organ transplantation.</a> The New England Journal of Medicine. 354, 2235-2249 (2006).</li><li>Flatz, L., Bergthaler, A., de la Torre, J. C., Pinschewer, D. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Recovery+of+an+arenavirus+entirely+from+RNA+polymerase+I/II-driven+cDNA.">Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA.</a> Proceedings of the National Academy of Sciences of the United States of America. 103, 4663-4668 (2006).</li><li>Gunther, S., Lenz, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lassa+virus.">Lassa virus.</a> Critical reviews in clinical laboratory sciences. 41, 339-390 (2004).</li><li>Harrison, L. H., Halsey, N. A., McKee, K. T., Peters, C. J., Barrera Oro, J. G., Briggiler, A. M., Feuillade, M. R., Maiztegui, J. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Clinical+case+definitions+for+Argentine+hemorrhagic+fever.">Clinical case definitions for Argentine hemorrhagic fever.</a> Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 28, 1091-1094 (1999).</li><li>Isaacson, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Viral+hemorrhagic+fever+hazards+for+travelers+in+Africa.">Viral hemorrhagic fever hazards for travelers in Africa.</a> Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 33, 1707-1712 (2001).</li><li>Kerber, R., Rieger, T., Busch, C., Flatz, L., Pinschewer, D. D., Kummerer, B. M., Gunther, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cross-species+analysis+of+the+replication+complex+of+Old+World+arenaviruses+reveals+two+nucleoprotein+sites+involved+in+L+protein+function.">Cross-species analysis of the replication complex of Old World arenaviruses reveals two nucleoprotein sites involved in L protein function.</a> Journal of Virology. 85, 12518-12528 (2011).</li><li>Lee, K. J., Novella, I. S., Teng, M. N., Oldstone, M. B., de La Torre, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=NP+and+L+proteins+of+lymphocytic+choriomeningitis+virus+(LCMV)+are+sufficient+for+efficient+transcription+and+replication+of+LCMV+genomic+RNA+analogs.">NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs.</a> Journal of Virology. 74, 3470-3477 (2000).</li><li>Mets, M. B., Barton, L. L., Khan, A. S., Ksiazek, T. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymphocytic+choriomeningitis+virus:+an+underdiagnosed+cause+of+congenital+chorioretinitis.">Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis.</a> American Journal of Ophthalmology. 130, 209-215 (2000).</li><li>Murakami, S., Horimoto, T., Yamada, S., Kakugawa, S., Goto, H., Kawaoka, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Establishment+of+canine+RNA+polymerase+I-driven+reverse+genetics+for+influenza+A+virus:+its+application+for+H5N1+vaccine+production.">Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production.</a> Journal of Virology. 82, 1605-1609 (2008).</li><li>Palacios, G., Druce, J., Du, L., Tran, T., Birch, C., Briese, T., Conlan, S., Quan, P. L., Hui, J., Marshall, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+new+arenavirus+in+a+cluster+of+fatal+transplant-associated+diseases.">A new arenavirus in a cluster of fatal transplant-associated diseases.</a> The New England Journal of Medicine. 358, 991-998 (2008).</li><li>Rodrigo, W. W., de la Torre, J. C., Martinez-Sobrido, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Use+of+single-cycle+infectious+lymphocytic+choriomeningitis+virus+to+study+hemorrhagic+fever+arenaviruses.">Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses.</a> Journal of Virology. 85, 1684-1695 (2011).</li><li>Rojek, J. M., Kunz, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cell+entry+by+human+pathogenic+arenaviruses.">Cell entry by human pathogenic arenaviruses.</a> Cellular Microbiology. 10, 828-835 (2008).</li><li>Rojek, J. M., Sanchez, A. B., Nguyen, N. T., de la Torre, J. C., Kunz, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Different+mechanisms+of+cell+entry+by+human-pathogenic+Old+World+and+New+World+arenaviruses.">Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses.</a> Journal of Virology. 82, 7677-7687 (2008).</li><li>Sanchez, A. B., de la Torre, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rescue+of+the+prototypic+Arenavirus+LCMV+entirely+from+plasmid.">Rescue of the prototypic Arenavirus LCMV entirely from plasmid.</a> Virology. 350, 370-380 (2006).</li></ol>

No conflicts of interest declared.

Generation of recombinant arenaviruses using plasmid-based reverse genetics techniques has become a widely used approach for the investigation of many different facets of arenavirus biology. Here we document a crucial improvement to the current system by performing arenavirus rescues in Vero cells, allowing for the potential generation of FDA-approved vaccine candidates against arenaviruses and vaccine vectors against other infectious diseases.
The experimental procedures involved are in gener...

Arenaviruses are enveloped viruses with a bisegmented, negative-stranded RNA genome 3 that belong to the Arenaviridae family. The arenavirus genome encodes four proteins in an ambisense fashion from two separate viral segments 3. The large (L) segment encodes the RNA-dependent RNA polymerase (L) and the small RING (Really Interesting New Gene) finger protein (Z) that serves as the main driving force of virus budding. The small (S) segment encodes the viral nucleoprotein (NP) and the surface glycoprotein (GP) (Figure 1).
Several members of the Arenaviridae family are responsible for lethal hemorrhagic fever (HF) in humans 3. Of principle concerns are Lassa virus (LASV) and Jun&iacute;n virus (JUNV), which are known to cause high mortality in hospitalized patients 8, 9 . Although these viruses are endemic to West Africa and rural Argentina, respectively, there are increasing concerns of importation of LASV and JUNV to non-endemic areas due to increased travel 10. Additionally, although not normally associated with severe disease in humans, the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is considered a neglected pathogen as there have been cases of lethal infection in immunocompromised patients 6, 15 and is responsible for congenital birth defects and spontaneous abortions in pregnant women 2, 13 . Currently there are no US FDA-approved vaccines against arenaviruses and treatment is limited to the nucleoside analog ribavirin, which is only partially effective and often associated with significant side effects.
The introduction of plasmid-based reverse genetics 4 and generation of recombinant arenaviruses 7, 19 have greatly advanced the field of arenavirus research. Currently, rodent cells (such as BHK-21) are used for the generation of recombinant arenaviruses due to the species-specific murine RNA polymerase I (pol-I) promoter directing the initial transcription of the S and L segments. However virus rescue in BHK-21 cells are not an approved method for the generation of recombinant arenaviruses as potential vaccine seed candidates. Here we document the use of the human pol-I promoter for efficient rescue of the prototypic Old World (OW) LCMV and the New World (NW) JUNV Candid#1 strain in Vero cells. Using a similar methodology, we generated recombinant trisegmented LCMV (r3LCMV) and Candid#1 (r3Candid#1) arenaviruses that contain two additional foreign genes encoded in two different S RNA segments 5 . This new system not only follows a highly reproducible and simple protocol but can be immediately implemented in the generation of recombinant arenaviruses as potential vaccine or vaccine vector seeds.

<table border="1">
	<tbody>
 <tr>
 <td></td>
 <td></td>
 <td></td>
 <td>Material and methods</td>
 </tr>
 <tr>
 <td></td>
 <td></td>
 <td></td>
 <td>
 Cell lines 
Vero E6 (African green monkey kidney epithelial cells) are maintained in a 37 &deg;C incubator with 5 % CO2 in DMEM 10 % FBS 1 % PS. Cells are available from the American Type Culture Collection (ATCC, catalogue number CRL-1586). 
 
Plasmids 
All plasmids, with the exception of hpol-I L, can be grown at 37 &deg;C, for 16-18 hr. We recommend that cultures of the hpol-I L be grown at 30 &deg;C for 24 hr. Plasmids are prepared using a plasmid maxi kit (EZNA Fastfilter Plasmid Maxi Kit, Omega Bio-tek) following the manufacturer's recommendations and stored at -20 &deg;C. The concentration of the purified DNA plasmid is determined by spectrophotometry at 260 nm, with purity being estimated using the 260:280 nm ratio. Preparations with 1.8-2.0 260:280 nm ratios are considered appropriate for virus rescue purposes. Additionally, plasmid concentration and purity should be confirmed with agarose gel electrophoresis. 
 
Viruses 
The described protocol for rescuing rLCMV (Armstrong 53b) and rCandid#1 can be executed under biosafety level (BSL) 2 conditions. Contaminated material, including TCS and cells should be sterilized before disposal. Rescue of other arenavirus may require higher BSL facilities so proper safety/security measures must be followed. 
 
Tissue culture media and solutions 
DMEM 10 %FBS 1 %PS: 445 ml Dulbecco's modified Eagle's medium (DMEM), 50 ml of Fetal Bovine Serum (FBS), and 5 ml of 100X Penicillin/Streptomycin (PS). Store at 4 &deg;C. This media will be used for maintenance of Vero cells. 
 
Infectious Media: 2-to-1 mixture of OptiMEM and DMEM 10 %FBS 1 %PS. Store at 4 &deg;C. This media will be used during viral infections. 
 
10X Phosphate buffered saline (PBS): 80 g of NaCl, 2 g of KCl, 11.5 g of Na2HPO4.7H2O, 2 g of KH2PO4. Add ddH2O up to 1 liter. Adjust pH to 7.3. Sterilize by autoclave. Store at room temperature. 
1X PBS: Dilute 10X PBS 1:10 with ddH2O. Sterilize by autoclave and store at room temperature. 
2.5 % BSA: 2.5 g of BSA in 97.5 ml of 1X PBS. Store at 4 &deg;C. This is used as a blocking solution for IFA.
</td>
 </tr>
 </tbody>
 </table>

generation of recombinant arenavirus for vaccine development in fda-approved vero cells

The development and implementation of arenavirus reverse genetics represents a significant breakthrough in the arenavirus field 4. The use of cell-based arenavirus minigenome systems together with the ability to generate recombinant infectious arenaviruses with predetermined mutations in their genomes has facilitated the investigation of the contribution of viral determinants to the different steps of the arenavirus life cycle, as well as virus-host interactions and mechanisms of arenavirus pathogenesis 1, 3, 11 . In addition, the development of trisegmented arenaviruses has permitted the use of the arenavirus genome to express additional foreign genes of interest, thus opening the possibility of arenavirus-based vaccine vector applications 5 . Likewise, the development of single-cycle infectious arenaviruses capable of expressing reporter genes provides a new experimental tool to improve the safety of research involving highly pathogenic human arenaviruses 16 . The generation of recombinant arenaviruses using plasmid-based reverse genetics techniques has so far relied on the use of rodent cell lines 7,19 , which poses some barriers for the development of Food and Drug Administration (FDA)-licensed vaccine or vaccine vectors. To overcome this obstacle, we describe here the efficient generation of recombinant arenaviruses in FDA-approved Vero cells.

Successful rescue of a recombinant wild-type arenavirus will be confirmed by the presence of viral antigens using IFA (Figure 5). In the case of recombinant trisegmented viruses, successful viral rescue can be assessed by observing GFP expression by fluorescence microscopy (Figure 6A). Successful rescue will be further confirmed by assessing Gluc expression (Figure 6B). Representative results illustrating the successful rescue of wild-type and trisegmented arenavirus wer...

Watch this Scientific Journal Video about Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells at JoVE.com

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human pathogenic arenaviruses.

The development and implementation of arenavirus reverse genetics represents a significant breakthrough in the arenavirus field  4. The use of cell-based ...

generation-recombinant-arenavirus-for-vaccine-development-fda

Research

JoVE Journal

Immunology and Infection

16.8K Views.  University of Rochester School of Medicine and Dentistry. Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe v...